sequenom inc (SQNM) Key Developments
Sequenom, Inc. Elects Catherine J. Mackey as New Member of its Board of Directors
Jun 18 15
Sequenom Inc. announced that its shareholders elected Catherine J. Mackey, Ph.D., as a new member of its Board of Directors, effective June 17, 2015. Dr. Mackey has also been appointed to the Audit and Nominating and Corporate Governance committees of the company's Board of Directors. Dr. Mackey is currently the Chief Executive Officer of CYPrus Therapeutics Inc.
Sequenom Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:30 PM
May 27 15
Sequenom Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: William J. Welch, Chief Executive Officer, President and Director.
Sequenom Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 6 15
Sequenom Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $37.8 million, an increase of 2% compared to $37.1 million for the first quarter of 2014. Net earnings improved to $14.3 million, or $0.11 per diluted share as compared to a net loss of $15.7 million, or $0.13 per share, basic and diluted, for the first quarter of 2014. The improvement in the net earnings from the prior year is due to a $21.0 million gain on the pooled patents agreement with Illumina Inc., as well as improved gross margins and reduced operating expenses compared to the prior year first quarter. Operating income was $16.5 million as compared to operating loss of $14.4 million for the same period in 2014. Net cash used in operating activities was $7.2 million an improvement compared to $16.1 million for the first quarter of 2014. Earnings from continuing operations before income taxes were $14,360,000 against loss from continuing operations before income taxes of $16,545,000 a year ago. Purchases of property, equipment and leasehold improvements were $289,000 against $405,000 a year ago.
Sequenom Inc. Proposes Amendment to its Restated Certificate of Incorporation
Apr 28 15
Sequenom Inc. announced that the annual general meeting to be held on June 17, 2015, it has proposed an amendment to the company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 185,000,000 to 275,000,000 shares.
Sequenom Inc., Annual General Meeting, Jun 17, 2015
Apr 28 15
Sequenom Inc., Annual General Meeting, Jun 17, 2015., at 09:00 Pacific Standard Time. Location: 3595 John Hopkins Court. Agenda: To elect Kenneth F. Buechler, Myla Lai-Goldman, Richard A. Lerner, Ronald M. Lindsay, Catherine J. Mackey, David Pendarvis, Charles P. Slacik, Dirk van den Boom and William J. Welch as directors to hold office until the annual meeting of stockholders in 2016; to approve an amendment to the company’s restated certificate of incorporation to increase the number of authorized shares of common stock from 185,000,000 to 275,000,000 shares; to approve the compensation of the company’s named executive officers; to ratify audit committee’s selection of Ernst & Young LLP to be independent registered public accounting firm for the fiscal year ending December 31, 2015; and to conduct any other business properly brought before the meeting or any adjournment or postponement thereof.